Dostarlimab
- Generic Name
- Dostarlimab
- Brand Names
- Jemperli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-59-2
- Unique Ingredient Identifier
- P0GVQ9A4S5
- Background
Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...
- Indication
Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...
- Associated Conditions
- Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
- Associated Therapies
- -
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03250832
- Locations
- π«π·
GSK Investigational Site, Villejuif cedex, France
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.